

# ANTICOAGULATION STEWARDSHIP: PROFILES IN PROGRESS

Hospitals throughout the United States have developed and implemented successful Anticoagulation Stewardship Programs. These programs have a positive financial impact and improve clinical outcomes for patients with thrombotic and hemostatic conditions. (All clinical outcomes presented are statistically significant)

## The Johns Hopkins Hospital Baltimore, Maryland

### Stewardship Model

- Implemented a multidisciplinary Hemostatic and Antithrombotic Stewardship program with a three-phase toolkit<sup>1</sup>
- Examples of interventions include fixed-dosing of PCCs, rFVIIa dose minimization, preferential use of aPCC for hemophilia patients with inhibitors, and continuous infusion FVIII, FIX, and VWF administration<sup>1</sup>

### Impact

- **\$3 million** estimated cost avoidance over two years<sup>1</sup>
- rFVIIa was the CFC product associated with the greatest cost avoidance<sup>1</sup>

## North Carolina Medical Center Chapel Hill, North Carolina

### Stewardship Model

- Developed a blood clotting factor stewardship program focused on optimization of product selection, dosing regimens, and infusion frequencies<sup>2</sup>
- Key steps included:
  - Narrowing blood clotting factor formulary
  - Established blood clotting factor prescribing guidelines
  - Instituted ongoing education of clinical staff

### Impact

- Exceeded **\$4 million** in cost savings annually<sup>2</sup>
- **45% ↓** in blood clotting factor doses annually<sup>2</sup>

## Jackson Memorial Hospital Miami, Florida

### Stewardship Model

- Implemented a full-service stewardship program with a PGY-1 resident transition of care service<sup>3</sup>

### Impact

- **\$270,000** cost savings over 8 months<sup>3</sup>
  - \$128,000 from argatroban monitoring<sup>3</sup>
  - \$151,000 from transition of care service<sup>3</sup>
- **1.4 day ↓** in LOS<sup>3</sup>
- **37%** of patients were inappropriately on argatroban with 70% of those changed to an appropriate agent<sup>3</sup>

## Brigham and Women's Hospital Boston, Massachusetts

### Stewardship Model

- Implemented a Hemostatic and Antithrombotic stewardship program to ensure appropriate use of DTIs in patients with HIT<sup>4</sup>

### Impact

- **\$250,000** cost savings in diagnosis and management of HIT<sup>4</sup>
- Duration of DTI use ↓ from 6.6 to 5.2 days<sup>4</sup>
- **45.7% ↓** in HIT tests performed and **28.6% ↓** in patients evaluated for HIT<sup>4</sup>

## Tufts Medical Center Boston, Massachusetts

### Stewardship Model

- Implemented a multidisciplinary blood clotting factor stewardship program focused on dispensing blood clotting factors from the pharmacy rather than the blood bank<sup>5</sup>

### Impact

- **\$100,000** cost savings over 6 months
  - Due to ↓ PCC and rFVIIa dispensing<sup>5</sup>

## Rochester General Hospital Rochester, New York

### Stewardship Model

- Implemented an inpatient anticoagulation team that oversaw anticoagulants, high-cost reversal agents, and HIT management<sup>6</sup>
- Intervention categories included PK/PD optimization, anticoagulation therapy optimization, and monitoring<sup>6</sup>

### Impact

- **\$1 million** cost savings annually<sup>6</sup>
- **10%** of anticoagulation cases resulted in improved care<sup>6</sup>
- **53.2% ↓** in inappropriate PCC orders<sup>6</sup>
  - Resulting in \$385,000 cost savings annually<sup>6</sup>

## The University of New Mexico Hospital Albuquerque, New Mexico

### Stewardship Model

- Implemented an inpatient pharmacy-driven anticoagulation management service and hospital reference laboratory to reduce HIT antibody testing through pharmacist intervention and the 4T pretest probability score<sup>7</sup>

### Impact

- **\$75,000** cost savings<sup>7</sup> or 62% per patient exposed to heparin<sup>7</sup>
- **81% ↓** in HIT Abs ordered and processed with no increase in ADEs<sup>7</sup>
- ↓ average length of DTI therapy per patient from **7.4 to 5.1 days**<sup>7</sup>

## Hackensack University Medical Center Hackensack, New Jersey

### Stewardship Model

- Developed a pharmacist-driven anticoagulation reversal program focused on appropriateness of reversal agents based on clinical scenario, optimization of selection, and avoidance of unintended consequences<sup>8</sup>

### Impact

- **52%** of cases had interventions<sup>8</sup>
- **\$1 million** total cost avoidance<sup>8</sup>
- Initial reversal agent requests were modified in 45% or denied in 13% of cases<sup>8</sup>
- **84%** hemostatic effectiveness<sup>8</sup>

#### Acronyms:

ADEs = adverse drug events; aPCC = activated prothrombin complex concentrate; CFC = clotting factor concentrate; DTI = direct thrombin inhibitor; FIX = Factor IX; FVIII = Factor VIII; HIT = heparin-induced thrombocytopenia; HIT Abs = heparin-induced thrombocytopenia antibody; LOS = length of stay; PCC = prothrombin complex concentrate; PGY-1 = post graduate year 1; PK/PD = pharmacokinetics/pharmacodynamics; rFVIIa = recombinant activated factor VIIa; VWF = Von Willebrand Factor.

To learn more about how you can help advance anticoagulation stewardship visit <https://acforum.org/web/education-stewardship.php>, scan the QR code to the right, or email [info@acforum.org](mailto:info@acforum.org).



## BIBLIOGRAPHY FOR: PROFILES IN PROGRESS RESOURCE

1. Reardon DP, Atay JK, Ashley SW, Churchill WW, Berliner N, Connors JM. Implementation of a Hemostatic and Antithrombotic Stewardship program. *J Thromb Thrombolysis*. 2015 Oct;40(3):379-82. doi: 10.1007/s11239-015-1189-3.
2. Amerine LB, Chen SL, Daniels R, Key N, Eckel SF, Savage SW. Impact of an innovative blood factor stewardship program on drug expense and patient care. *Am J Health Syst Pharm*. Sep 15 2015;72(18):1579-84. doi:10.2146/ajhp140722
3. Padron M, Miyares MA. Development of an anticoagulation stewardship program at a large tertiary care academic institution. *J Pharm Pract*. 2015 Feb;28(1):93-8. doi: 10.1177/0897190013514091.
4. Ritchie BM, Sylvester KW, Reardon DP, Churchill WW, Berliner N, Connors JM. Treatment of heparin-induced thrombocytopenia before and after the implementation of a hemostatic and antithrombotic stewardship program. *J Thromb Thrombolysis*. 2016 Nov;42(4):616-22. doi: 10.1007/s11239-016-1408-6.
5. Waheed A, Fongemie J, Gopal S, Esham KS, Richardson-Weber L, Zhang L, Van Doren L, Buchsbaum RJ, Comenzo RL. Implementation and impact of a multidisciplinary coagulation factor stewardship program at an academic medical center. *J Thromb Thrombolysis*. 2020 Oct;50(3):715-717. doi: 10.1007/s11239-020-02071-1.
6. Wychowski MK, Ruscio CI, Kouides PA, Sham RL. The scope and value of an anticoagulation stewardship program at a community teaching hospital. *J Thromb Thrombolysis*. 2017 Apr;43(3):380-386. doi: 10.1007/s11239-016-1455-z.
7. Burnett AE, Bowles H, Borrego ME, Montoya TN, Garcia DA, Mahan C. Heparin-induced thrombocytopenia: reducing misdiagnosis via collaboration between an inpatient anticoagulation pharmacy service and hospital reference laboratory. *J Thromb Thrombolysis*. 2016 Nov;42(4):471-8.
8. Procopio GL, Jain RP, Tompkins DM, Perez JM, Bicking K. Impact of a pharmacist driven anticoagulation reversal program at a large academic medical center. *J Thromb Thrombolysis*. 2022 Jan;53(1):158-166. doi: 10.1007/s11239-021-02491-7.

To learn more about how you can help advance anticoagulation stewardship visit <https://acforum.org/web/education-stewardship.php>, scan the QR code to the right, or email [info@acforum.org](mailto:info@acforum.org).

